This Bull Market Indicator called NVDA at $116

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

David Pendarvis Biography and Net Worth

Insider of ResMed

David Pendarvis was appointed Chief Administrative Officer and Global General Counsel in May 2011. In addition to those roles, he served as Interim President for ResMed’s EMEA and Japan regions from March to August 2017. He joined ResMed as Global General Counsel in September 2002, and has been Corporate Secretary since February 2003. From 2005 to 2011, he served as senior Vice President of Organisational Development.

Before joining ResMed, David was a partner in the law firm Gray Cary Ware & Freidenrich LLP from 2000 to 2002, where he specialised in intellectual property and general business litigation. From 1986 to 2000, he was a partner at Gibson, Dunn & Crutcher LLP. From 1984 to 1986, he was a law clerk to the Hon. J. Lawrence Irving, US District Judge, Southern District of California.

David was elected to the board of directors of WD-40 Company (NASDAQ: WDFC) in December 2017. He has also served on the board of directors of the San Diego Regional Chamber of Commerce since 2013 and the Corporate Directors Forum since 2010. From 2009 to 2016, he was a director on the board of Sequenom, Inc.

David holds a Bachelor of Arts from Rice University; a Juris Doctor (J.D.), cum laude, from the University of Texas School of Law; a Master of Science in executive leadership from the University of San Diego; and a bachelor’s in political science and managerial studies from Rice University.

What is David Pendarvis' net worth?: The estimated net worth of David Pendarvis is at least $1.20 million as of April 12th, 2024. Mr. Pendarvis owns 4,934 shares of ResMed stock worth more than $1,197,136 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Pendarvis may own. Learn More about David Pendarvis' net worth.
How do I contact David Pendarvis?: The corporate mailing address for Mr. Pendarvis and other ResMed executives is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. ResMed can also be reached via phone at (858) 836-5000 and via email at [email protected]. Learn More on David Pendarvis' contact information.
Has David Pendarvis been buying or selling shares of ResMed?: David Pendarvis has not been actively trading shares of ResMed in the last ninety days. Most recently, David Pendarvis sold 1,500 shares of the business's stock in a transaction on Monday, June 5th. The shares were sold at an average price of $219.79, for a transaction totalling $329,685.00. Following the completion of the sale, the insider now directly owns 89,729 shares of the company's stock, valued at $19,721,536.91. Learn More on David Pendarvis' trading history.
Who are ResMed's active insiders?: ResMed's insider roster includes Carol Burt (Director), Jan De Witte (Director), Robert Douglas (COO), Karen Drexler (Director), Michael Farrell (CEO), Peter Farrell (Director), Kaushik Ghoshal (Insider), James Hollingshead (Insider), Justin Leong (Insider), David Pendarvis (Insider), Michael Rider (General Counsel), Brett Sandercock (CFO), Rajwant Sodhi (Insider), and Ronald Taylor (Director). Learn More on ResMed's active insiders.
Are insiders buying or selling shares of ResMed?: In the last twelve months, insiders at the medical equipment provider sold shares 27 times. They sold a total of 187,789 shares worth more than $41,061,987.20. The most recent insider tranaction occured on November, 12th when Director Witte Jan De sold 796 shares worth more than $198,052.76. Insiders at ResMed own 0.7% of the company. Learn More about insider trades at ResMed.
Information on this page was last updated on 11/12/2024.

David Pendarvis Insider Trading History at ResMed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/5/2023	Sell	1,500	$219.79	$329,685.00	89,729
5/3/2023	Sell	1,500	$237.64	$356,460.00	91,172
4/3/2023	Sell	1,500	$218.23	$327,345.00	92,672
3/3/2023	Sell	1,500	$216.69	$325,035.00	94,172
2/3/2023	Sell	1,500	$224.50	$336,750.00	95,672
1/3/2023	Sell	1,500	$210.07	$315,105.00	97,172
12/5/2022	Sell	1,500	$229.81	$344,715.00	98,672
11/3/2022	Sell	1,545	$215.23	$332,530.35	102,334
10/3/2022	Sell	1,545	$220.19	$340,193.55	103,879
8/3/2022	Sell	1,545	$240.72	$371,912.40	105,286
7/5/2022	Sell	1,545	$212.33	$328,049.85	106,831
6/3/2022	Sell	1,545	$209.44	$323,584.80	108,376
5/3/2022	Sell	1,545	$200.00	$309,000.00	109,858
3/3/2022	Sell	1,544	$250.62	$386,957.28
2/3/2022	Sell	1,544	$232.87	$359,551.28
12/3/2021	Sell	1,544	$257.93	$398,243.92
11/3/2021	Sell	1,485	$264.29	$392,470.65
10/4/2021	Sell	1,487	$260.79	$387,794.73
9/3/2021	Sell	1,487	$292.16	$434,441.92	123,959
7/6/2021	Sell	1,487	$247.12	$367,467.44	124,900
6/3/2021	Sell	1,487	$207.00	$307,809.00
4/5/2021	Sell	1,487	$196.15	$291,675.05	129,294
12/3/2020	Sell	1,487	$208.36	$309,831.32	133,694
10/5/2020	Sell	5,919	$170.07	$1,006,644.33	142,047
9/3/2020	Sell	5,919	$177.52	$1,050,740.88	142,047
7/6/2020	Sell	5,919	$194.64	$1,152,074.16	139,861
6/3/2020	Sell	5,919	$160.61	$950,650.59	136,322
5/4/2020	Sell	4,737	$155.06	$734,519.22	135,379
2/3/2020	Sell	4,739	$162.37	$769,471.43	135,303
11/4/2019	Sell	4,367	$147.85	$645,660.95	128,781
10/3/2019	Sell	4,367	$128.62	$561,683.54	126,618
9/3/2019	Sell	4,367	$138.11	$603,126.37	126,618
8/5/2019	Sell	4,367	$128.56	$561,421.52	122,250
7/3/2019	Sell	4,367	$123.86	$540,896.62	122,250
6/3/2019	Sell	4,367	$114.01	$497,881.67	117,883
5/3/2019	Sell	4,367	$112.58	$491,636.86
4/3/2019	Sell	4,457	$105.21	$468,920.97	122,459
3/4/2019	Sell	4,457	$103.61	$461,789.77	122,459
2/4/2019	Sell	4,457	$93.50	$416,729.50
11/5/2018	Sell	2,810	$105.97	$297,775.70
10/3/2018	Sell	2,810	$113.95	$320,199.50	107,061
8/3/2018	Sell	2,810	$106.20	$298,422.00	101,893
6/4/2018	Sell	2,810	$103.75	$291,537.50
5/3/2018	Sell	2,810	$95.91	$269,507.10	98,043
3/5/2018	Sell	2,810	$94.08	$264,364.80	97,263
2/5/2018	Sell	2,810	$96.03	$269,844.30	97,263
12/4/2017	Sell	2,804	$84.17	$236,012.68	97,257
11/3/2017	Sell	6,364	$82.20	$523,120.80
10/3/2017	Sell	6,364	$76.94	$489,646.16
9/5/2017	Sell	6,364	$77.21	$491,364.44	93,172
8/3/2017	Sell	6,364	$72.10	$458,844.40	84,476
7/3/2017	Sell	6,364	$77.36	$492,319.04	84,476
6/5/2017	Sell	6,365	$72.62	$462,226.30	84,477
5/3/2017	Sell	6,365	$69.55	$442,685.75	84,261
4/3/2017	Sell	6,365	$71.59	$455,670.35	84,261
2/3/2017	Sell	6,365	$67.16	$427,473.40	84,261
1/3/2017	Sell	6,365	$61.95	$394,311.75	84,261
12/5/2016	Sell	6,365	$60.00	$381,900.00	84,261
11/3/2016	Sell	6,033	$57.79	$348,647.07
10/3/2016	Sell	6,000	$63.95	$383,700.00	87,061
9/6/2016	Sell	6,000	$67.18	$403,080.00	87,061
8/3/2016	Sell	6,000	$68.86	$413,160.00	80,512
7/5/2016	Sell	6,000	$63.62	$381,720.00	80,512
6/3/2016	Sell	6,000	$59.41	$356,460.00	80,512
5/3/2016	Sell	6,000	$56.02	$336,120.00	80,287
4/4/2016	Sell	6,000	$58.70	$352,200.00	80,287
3/3/2016	Sell	6,000	$57.26	$343,560.00	80,287
2/3/2016	Sell	6,000	$57.43	$344,580.00	74,287
1/4/2016	Sell	6,000	$52.16	$312,960.00	74,287
12/3/2015	Sell	6,000	$59.38	$356,280.00	74,287
10/5/2015	Sell	5,500	$52.47	$288,585.00	77,180
9/3/2015	Sell	5,500	$51.78	$284,790.00	77,180
7/6/2015	Sell	5,500	$55.19	$303,545.00
6/3/2015	Sell	5,500	$59.41	$326,755.00
5/4/2015	Sell	5,500	$65.10	$358,050.00
4/6/2015	Sell	5,500	$72.60	$399,300.00
2/5/2015	Sell	5,500	$62.35	$342,925.00
1/5/2015	Sell	5,500	$57.09	$313,995.00
11/3/2014	Sell	3,557	$52.00	$184,964.00
10/3/2014	Sell	5,000	$49.84	$249,200.00
9/3/2014	Sell	5,000	$53.23	$266,150.00
8/4/2014	Sell	5,000	$49.12	$245,600.00
7/3/2014	Sell	5,000	$50.04	$250,200.00
6/3/2014	Sell	5,000	$49.76	$248,800.00
4/29/2014	Sell	15,000	$50.01	$750,150.00	68,956
4/4/2014	Sell	5,000	$44.95	$224,750.00	68,956
10/29/2013	Sell	37,744	$50.42	$1,903,052.48

David Pendarvis Buying and Selling Activity at ResMed

ResMed Company Overview

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Today's Range

Now: $242.63

$241.35

$242.63

50 Day Range

MA: $242.10

$231.43

$256.07

2 Week Range

Now: $242.63

$151.95

$260.49

Volume

16,226 shs

Average Volume

1,039,342 shs

Market Capitalization

$35.62 billion

P/E Ratio

32.14

Dividend Yield

0.89%

Beta

0.69